Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3

Osteoporosis is a debilitating skeletal disorder that is characterized by loss of bone densityover time. It affects one in two women and one in four men, age 50 and older. New treatmentsthat specifically drive bone formation are desperately needed. We developed a peptide, CK2.3, thatacts downstream...

Full description

Bibliographic Details
Main Authors: Vrathasha Vrathasha, Karl Booksh, Randall L. Duncan, Anja Nohe
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:Nanomaterials
Subjects:
Online Access:http://www.mdpi.com/2079-4991/8/7/513
id doaj-6705e3581c664d2987ad1f828888add9
record_format Article
spelling doaj-6705e3581c664d2987ad1f828888add92020-11-24T21:58:38ZengMDPI AGNanomaterials2079-49912018-07-018751310.3390/nano8070513nano8070513Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3Vrathasha Vrathasha0Karl Booksh1Randall L. Duncan2Anja Nohe3Department of Biological Sciences, University of Delaware, Newark, DE 19716, USADepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716, USADepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USADepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USAOsteoporosis is a debilitating skeletal disorder that is characterized by loss of bone densityover time. It affects one in two women and one in four men, age 50 and older. New treatmentsthat specifically drive bone formation are desperately needed. We developed a peptide, CK2.3, thatacts downstream of the bone morphogenetic protein receptor type Ia and it induces osteogenesisin-vitro and in-vivo. However, its mechanism of action, especially its mode of uptake by cellsremains unknown. To demonstrate CK2.3 internalization within a cell, we conjugated CK2.3to Quantum Dot®s (Qdot®s), semiconductor nanoparticles. We purified CK2.3-Qdot®s by sizeexclusion chromatography and verified the conjugation and stability using UV/VIS and Fouriertransform infrared spectroscopy. Our results show that CK2.3 was conjugated to the Qdot®s andthe conjugate was stable for at least 4 days at 37 °C. Moreover, CK2.3-Qdot®s exerted biologicalresponse similar to CK2.3. Addition of CK2.3-Qdot®s to cells followed by confocal imaging revealedthat CK2.3-Qdot®s were internalized at 6 h post stimulation. Furthermore, using pharmacologicalinhibitors against endocytic pathways, we demonstrated that CK2.3-Qdot®s were internalized bycaveolae. These results show for the first time that the novel peptide CK2.3 is taken up by the cellthrough caveolae mediated endocytosis.http://www.mdpi.com/2079-4991/8/7/513BoneOsteoporosisCK2.3Qdot®sFluorescence imagingFTIR
collection DOAJ
language English
format Article
sources DOAJ
author Vrathasha Vrathasha
Karl Booksh
Randall L. Duncan
Anja Nohe
spellingShingle Vrathasha Vrathasha
Karl Booksh
Randall L. Duncan
Anja Nohe
Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
Nanomaterials
Bone
Osteoporosis
CK2.3
Qdot®s
Fluorescence imaging
FTIR
author_facet Vrathasha Vrathasha
Karl Booksh
Randall L. Duncan
Anja Nohe
author_sort Vrathasha Vrathasha
title Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
title_short Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
title_full Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
title_fullStr Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
title_full_unstemmed Mechanisms of Cellular Internalization of Quantum Dot® Conjugated Bone Formation Mimetic Peptide CK2.3
title_sort mechanisms of cellular internalization of quantum dot® conjugated bone formation mimetic peptide ck2.3
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2018-07-01
description Osteoporosis is a debilitating skeletal disorder that is characterized by loss of bone densityover time. It affects one in two women and one in four men, age 50 and older. New treatmentsthat specifically drive bone formation are desperately needed. We developed a peptide, CK2.3, thatacts downstream of the bone morphogenetic protein receptor type Ia and it induces osteogenesisin-vitro and in-vivo. However, its mechanism of action, especially its mode of uptake by cellsremains unknown. To demonstrate CK2.3 internalization within a cell, we conjugated CK2.3to Quantum Dot®s (Qdot®s), semiconductor nanoparticles. We purified CK2.3-Qdot®s by sizeexclusion chromatography and verified the conjugation and stability using UV/VIS and Fouriertransform infrared spectroscopy. Our results show that CK2.3 was conjugated to the Qdot®s andthe conjugate was stable for at least 4 days at 37 °C. Moreover, CK2.3-Qdot®s exerted biologicalresponse similar to CK2.3. Addition of CK2.3-Qdot®s to cells followed by confocal imaging revealedthat CK2.3-Qdot®s were internalized at 6 h post stimulation. Furthermore, using pharmacologicalinhibitors against endocytic pathways, we demonstrated that CK2.3-Qdot®s were internalized bycaveolae. These results show for the first time that the novel peptide CK2.3 is taken up by the cellthrough caveolae mediated endocytosis.
topic Bone
Osteoporosis
CK2.3
Qdot®s
Fluorescence imaging
FTIR
url http://www.mdpi.com/2079-4991/8/7/513
work_keys_str_mv AT vrathashavrathasha mechanismsofcellularinternalizationofquantumdotconjugatedboneformationmimeticpeptideck23
AT karlbooksh mechanismsofcellularinternalizationofquantumdotconjugatedboneformationmimeticpeptideck23
AT randalllduncan mechanismsofcellularinternalizationofquantumdotconjugatedboneformationmimeticpeptideck23
AT anjanohe mechanismsofcellularinternalizationofquantumdotconjugatedboneformationmimeticpeptideck23
_version_ 1725851026518441984